Abstract Library

#4639 Prevalence and characteristics of incidental NET of the Meckel’s diverticula: Retrospective cohort study at a tertiary centre

Introduction: Meckel’s diverticulum is a rare finding in adults but can harbour malignancies such as leiomyosarcoma or neuroendocrine tumours (NET). The clinical presentation and tumour characteristics, including grading, have shown high variability in recent studies for NET.

Conference:

Presenting Author: Berckenhagen L

Authors: Berckenhagen L, Weidemann S, Amin T, Ritter A, Poppinga J,

Keywords: Meckel’s diverticula, incidental NET, acute abdomen, lower GI-bleeding,

#4618 The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumours

Introduction: Colonic neuroendocrine tumours (NETs), excluding rectal NETs, are often described as relatively common and aggressive, with inferior median survival compared to other gastrointestinal (GI) primary sites. However, epidemiological databases may conflate well-differentiated NETs with poorly differentiated NECs, leading to unclear data on prevalence, clinical behaviour, and prognosis of well-differentiated colonic NETs.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Strosberg J,

Keywords: colon, neuroendocrine tumour, caecum, sigmoid, neuroendocrine neoplasm,

#4604 Germline predisposition to neuroendocrine tumours of the pancreas (pNEN) based on mutations in DNA repair genes – BRCA1, BRCA2, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11

Introduction: Neuroendocrine tumours of the pancreas (pNEN) rank as the second most common epithelial neoplasms after pancreatic adenocarcinoma, with increasing prevalence and a mortality rate of 60%. Identifying germline mutations in DNA repair genes such as CHEK2, BRCA1/2, and MUTYH within pNEN cases may pave the way for personalised diagnostics and therapies.

Conference:

Presenting Author:

Authors: Jurecka Lubieniecka B, Ros-Mazurczyuk M, Oczko-Wojciechowska M, Cortez A, Handkiewicz-Junak D,

Keywords: pNEN, DNA repair genes,

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,

#4468 Prevalence of familial pheochromocytoma and paraganglioma syndromes – A large multicentre study

Introduction: Pheochromocytoma and paraganglioma (PPGLs) are rare tumours. Depending on the studied population, approximately 30% of PPGLs are caused by a germline pathogenic variant (PV).

Conference:

Presenting Author: Halperin R

Authors: Halperin R, Reznick-Levi G, Khalaileh A, Svirsky-Frayden R, Reish O,

Keywords: paraganglioma, pheochromocytoma, genetic evaluation, catecholamine, sdhb, vhl,